| Exosome-enclosed microRNAs in exhaled breath hold potential for biomarker discovery in patients with pulmonary diseases A Sinha, AK Yadav, S Chakraborty, SK Kabra, R Lodha, M Kumar, ... Journal of allergy and clinical immunology 132 (1), 219-222. e7, 2013 | 96 | 2013 |
| Chemical chaperones mitigate experimental asthma by attenuating endoplasmic reticulum stress L Makhija, V Krishnan, R Rehman, S Chakraborty, S Maity, U Mabalirajan, ... American journal of respiratory cell and molecular biology 50 (5), 923-931, 2014 | 63 | 2014 |
| Therapeutic targeting of the inflammasome in myeloid malignancies S Chakraborty, LC Shapiro, S de Oliveira, B Rivera-Pena, A Verma, ... Blood cancer journal 11 (9), 152, 2021 | 19 | 2021 |
| Genetic variations in olfactory receptor gene OR2AG2 in a large multigenerational family with asthma S Chakraborty, P Dakle, A Sinha, S Vishweswaraiah, A Nagori, ... Scientific reports 9 (1), 19029, 2019 | 15 | 2019 |
| Haplotype analysis of ADAM33 polymorphisms in asthma: A pilot study S Vishweswaraiah, NB Ramachandra, BS Jayaraj, AD Holla, ... The Indian Journal of Medical Research 150 (3), 272, 2019 | 11 | 2019 |
| The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia JD Gonzalez-Lugo, S Chakraborty, A Verma, A Shastri Seminars in hematology 58 (1), 56-65, 2021 | 7 | 2021 |
| Molecular and genomic basis of bronchial asthma A Gupta, S Chakraborty, A Agrawal Clinical Molecular Medicine, 353-366, 2020 | 6 | 2020 |
| Association between ADAM33 Single-Nucleotide Polymorphisms and Treatment Response to Inhaled Corticosteroids and a Long-Acting Beta-Agonist in Asthma S Vishweswaraiah, NB Ramachandra, N Joshi, A Parthasarathi, ... Diagnostics 13 (3), 405, 2023 | 4 | 2023 |
| Oxidative Stress-Induced Mitochondrial Dysfunction and Asthma S Chakraborty, K Khanna, A Agrawal Oxidative Stress in Lung Diseases: Volume 2, 141-160, 2020 | 2 | 2020 |
| A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia S Chakraborty, C Morganti, J Dey, H Zhang, S Aluri, N Gitego, K Pradhan, ... Blood 142, 2787, 2023 | 1 | 2023 |
| Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML BL Rivera, S Chakraborty, Y Shi, H Zhang, GS Choudhary, S Gordon, ... Blood 140 (Supplement 1), 6892-6893, 2022 | 1 | 2022 |
| P2. 11-17 MicroRNAs in Exhaled Breath Condensate and Bronchial Brushings as Biomarkers for Early Diagnosis of Lung Cancer RG B Pattnaik, S Chakraborty, P Bajpai, A Agrawal Journal of Thoracic Oncology 13 (10), S784-S785, 2018 | 1 | 2018 |
| A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML A Shastri, S Chakraborty, C Morganti, H Zhang, B Rivera-Pena, K Ito, ... Leukemia Research Reports 21, 100445, 2024 | | 2024 |
| GDF11/SMAD Regulated Splicing of GATA1 Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR-MDS) S Aluri, E Fraint, S Chakraborty, A Ahsan, G Poigailwar, R Zhao, ... Blood 142, 318, 2023 | | 2023 |
| Mechanisms of Resistance to Hypomethylating Agents And BCL-2 inhibitors SR Desai, S Chakraborty, A Shastri Best Practice & Research Clinical Haematology, 101521, 2023 | | 2023 |
| MDS-156 Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML B Rivera-Peña, S Chakraborty, Y Shi, H Zhang, R Zhao, G Choudhary, ... Clinical Lymphoma Myeloma and Leukemia 23, S355, 2023 | | 2023 |
| POSTER: MDS-156 Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML B Rivera-Peña, S Chakraborty, Y Shi, H Zhang, R Zhao, G Choudhary, ... Clinical Lymphoma Myeloma and Leukemia 23, S181, 2023 | | 2023 |
| P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY S Aluri, A Ahsan, S Hayati, M Ugidos, P Shah, K Lizotte, S Chakraborty, ... HemaSphere 7 (S3), e8463948, 2023 | | 2023 |
| PYRIMETHAMINE, A STAT3 INHIBITOR, HAS SYNERGY WITH VENETOCLAX AND IS EFFICACIOUS IN HYPOMETHYLATING AGENT RESISTANT MDS/AML A Shastri, H Zhang, B Rivera-Pena, S Chakraborty Leukemia Research 128, 107120, 2023 | | 2023 |
| A Transgenic Murine Model Expressing Hyperactive STAT3 Recapitulates the Features of MDS/AML BL Rivera, S Gordon, S Aluri, Y Shi, S Chakraborty, GS Choudhary, ... Blood 138, 3308, 2021 | | 2021 |
Aditi shastriMontefiore Medical Center在 montefiore.org 的电子邮件经过验证
